2024
Treatment patterns and clinical outcomes in patients with EGFR-mutated non-small cell lung cancer after progression on osimertinib
Robinson N, Canavan M, Zhan P, Udelsman B, Pathak R, Boffa D, Goldberg S. Treatment patterns and clinical outcomes in patients with EGFR-mutated non-small cell lung cancer after progression on osimertinib. Clinical Lung Cancer 2024 PMID: 39462746, DOI: 10.1016/j.cllc.2024.09.006.Peer-Reviewed Original ResearchNon-small cell lung cancerEGFR-mutant non-small cell lung cancerFirst-line osimertinibContinuation of osimertinibImmune checkpoint inhibitorsTyrosine kinase inhibitorsCell lung cancerRetrospective cohort studyOverall survivalTreatment regimensLung cancerAdvanced epidermal growth factor receptorAssociated with increased PFSAssociated with superior PFSSecond-line treatment regimenEGFR exon 19 deletionRetrospective cohort study of patientsEGFR tyrosine kinase inhibitorsAssociated with prolonged survivalCohort study of patientsSecond-line treatment regimensExon 19 deletionFirst-line therapyEpidermal growth factor receptorFirst-line treatment
2020
The association between initial chemotherapy treatment timing, intensity, and end-of-life (EOL) care trajectory among older adults with advanced stage lung cancer (aLC).
Presley C, Shahzad H, Canavan M, Prsic E, Saphire M, Wang S, Davidoff A. The association between initial chemotherapy treatment timing, intensity, and end-of-life (EOL) care trajectory among older adults with advanced stage lung cancer (aLC). Journal Of Clinical Oncology 2020, 38: e24009-e24009. DOI: 10.1200/jco.2020.38.15_suppl.e24009.Peer-Reviewed Original ResearchAdvanced-stage lung cancerDoublet chemotherapyEOL groupOlder adultsIntensity groupInitial chemotherapy regimenInitial chemotherapy treatmentPlatinum-based doubletsPlatinum-doublet chemotherapyFirst-line therapyUse of chemotherapyMajority of patientsEOL care preferencesStage lung cancerMain outcome measuresNon-Hispanic whitesMedicare registryChemotherapy regimenLine therapyCisplatin chemotherapyLung cancerChemotherapy treatmentAge 66Outcome measuresCare trajectories